Trulicity (dulaglutide) is a drug belonging to the glucagon-like peptide-1 receptor agonist (GLP-1) class of medications. Diabetes affects 38.4 million people in the United States, or 11.6% of the ...

Please provide your email address to receive an email when new articles are posted on . Risk for major adverse CV events was similar for adults receiving tirzepatide vs. dulaglutide. All-cause ...

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial, ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

Tirzepatide was noninferior to dulaglutide for the primary endpoint of time to first occurrence of death from cardiovascular causes, myocardial infarction, or stroke. Topline data were announced from ...

According to Novo Nordisk, this study was the first to compare these GLP-1 receptor agonists in a real-world setting. Findings from a real-world study evaluating cardiovascular disease-related ...